Graphite Bio
South San Francisco · Founded 2020
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $195.7M
- Funding stage: M&A
- Last round: Series B (Mar 2021)
- Ticker: nasdaq:GRPH
- Website: https://graphitebio.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/graphite-bio-73087 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.